<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the changes of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers CEA and CA19.9 as early predictors of progression in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev) </plain></SENT>
<SENT sid="1" pm="."><plain>Seventy-two patients had high baseline CEA or CA19.9 serum levels </plain></SENT>
<SENT sid="2" pm="."><plain>By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> versus SD/PR/CR </plain></SENT>
<SENT sid="3" pm="."><plain>Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev </plain></SENT>
</text></document>